Technology Insights Grenfell Fire
Design Wisdom
Smoke Integrity
Evacuation
Asthma is an allergic reaction by the human body to airborne or contact particles. Daily medicine
treatment is required, generally by deposition in the lung, aside from Merck’s tablet. The lung
route for broncho-dilators using active delivery by propellant or portable nebulisers is effective
upper airway emergency medicine. Inhaler systems are designed to deliver ~100ug in sub 3
micron particles to the lung periphery, there crossing the epithelium into the blood stream
Micronised dry powder is most often the active ingredient form for asthma treatments. Capsule systems require dexterity to use; open-inhale-close MDPl’s are more widely acceptable.
Some actives (API) are soluble in HFA so tend
to favour the pMDI route, otherwise
suspension
formulations have to
be
developed. Liquid metering valve technology
using low-GWP propellants is the low-carbon
future.
DDI breath-activated systems with counters
are the
most complex delivery DMDI
technology
electronic mesh nebulisers
aside.
Small molecules, combination treatments, triples, 4 drug systems, soft mist nebuliser, low-gap propellants